Migraine

Migraine is arguably the most common neurological condition, affecting up to 80% of adults at some time in their lives.

Condition(s) Type of Drug Phase Add-On Placebo Duration Open-Label Extension
Treatment-resistant migraine prevention Approved Emgality monthly injection III Yes 50% 3 months 3 months
Abortive therapy for acute migraine Oral combination of two approved drugs III Yes 33% 12 weeks None

Response Form

If you or a loved one is interested in participating in one of our trials, please contact us at (855) 829-8899 or use the form below. One of our skilled Clinical Research Coordinators will contact you as soon as possible. Thank you for your interest in our research!

- Stephen S. Flitman, MD, Medical Director

Your Name
Name of Patient
Email Address
Your Telephone
Best Time to Call
Comments
 Ready?